Raising Awareness for Biosimilars for Stakeholders Around the World

Monday November 14, 2022

Washington, D.C. (November 14, 2022) – AAM’s Biosimilars Council and other members of the International Generic and Biosimilar Medicines Association (IGBA) are working to increase awareness of biosimilars through the third annual Global Biosimilars Week, which takes place November 14-18. AAM’s Senior Director of Marketing, Erica Klinger, serves as the IGBA Chair of Global Biosimilars Week, spearheading efforts to raise awareness of biosimilars on social media:

“Since it first launched in 2020, Global Biosimilars Week has grown to include more than 150 organizations worldwide. We want to DOUBLE this engagement in 2022 and make GBW bigger than ever by increasing social media engagement using the hashtag #GlobalBiosimilarsWeek. Together, we can raise the profile of biosimilar medicines and help increase access for patients in the U.S.”

Join the global biosimilars community to raise awareness about these life-savings medicines – For detailed descriptions of the Global Biosimilars Week daily themes, sample social posts, graphics, and other resources, visit https://www.globalbiosimilarsweek.org/.

For more about the collaborative effort and release of the new IGBA White Paper, entitled Embracing Science with Confidence: Adopting the Revised 2022 WHO Biosimilars Guideline, read the statement by IGBA on https://www.igbamedicines.org/news/186-igba-reiterates-its-yearly-call-to-join-the-biosimilars-movement-on-advancing-access-november-2022 and included below:


IGBA Reiterates its Yearly Call to Join the Biosimilars Movement on Advancing Access

Geneva, November 14, 2022 – In the week ahead, IGBA will renew its commitment to the collaborative effort to establish worldwide biosimilar policies that deliver better health outcomes and biologics access equity for more patients. The third Global Biosimilars Week will run from 14th to 18th November, 2022 on social media, supported by a rich resource dedicated website globalbiosimilarsweek.org.

This awareness campaign is open to all stakeholder contributions worldwide and seeks to release and gather, under one hashtag #globalbiosimilarsweek, useful ideas, experience, interviews, information and resources for and from patients, doctors and all other stakeholders across the global healthcare community. The campaign theme this year isStrengthening Healthcare | The value of biosimilar medicines for patients, healthcare professionals, providers, governments and healthcare systems, as well as regulators.

The IGBA takes therefore the opportunity to release its new White Paper, entitled Embracing Science with Confidence: Adopting the Revised 2022 WHO Biosimilars Guideline. This paper, developed by the IGBA Biosimilars Committee, further elaborates on one of the four key areas identified in the IGBA’s 2021 Biosimilar medicines Access Policy Blueprint, namely enhancing regulatory efficiencies for greater access.

“This paper highlights how the revised 2022 WHO Biosimilars Guideline provides Clarity, Consistency and Confidence in state-of-the-art regulatory science for biosimilar medicines based on vast cumulated experience and over 1 million patient-treatment years of safety data in Europe alone”, explained Julie Maréchal-Jamil, Co-Chair of the Biosimilars Committee. “We welcome this science-based evolution of the WHO guideline as a driver for efficiency gains in biosimilar regulatory processes which we know will have a direct impact on the ability of patients to benefit from timely access to biologic therapies, “ she added.

“Now we need the national regulatory authorities to promptly re-examine their requirements. If cohesively adopted, the WHO Guideline can promote efficient regulatory systems to provide patients with earlier access to safe, effective, quality-assured, and lower-cost biosimilar medicines,” concluded Vivian Frittelli, IGBA Chair.

IGBA companies are the pioneers and global leaders in the development and marketing of biosimilar medicines. To date there have been 600 biosimilar approvals in IGBA’s membership jurisdictions plus Singapore and Switzerland, covering more than 10 therapeutic areas including oncology, rheumatoid arthritis, psoriasis, inflammatory bowel disease, growth disorders, nephrology, fertility, diabetes and ophthalmology.

About IGBA: The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org.


About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.